Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.83 |
| ▸ | JAK1 | P23458 | 2/20 | 0.83 |
| ▸ | JAK2 | O60674 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21948338 | 1.00 | TYK2 (0.83) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| SCHEMBL21961238 | 1.00 | TYK2 (0.83) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| Zasocitinib SCHEMBL31710036 | 0.91 | TYK2 (1.00) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| Zasocitinib SCHEMBL20678925 | 0.91 | TYK2 (1.00) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| Zasocitinib SCHEMBL20678921 | 0.91 | TYK2 (1.00) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| Zasocitinib SCHEMBL20678885 | 0.91 | TYK2 (1.00) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| Zasocitinib SCHEMBL20697064 | 0.91 | TYK2 (1.00) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| Zasocitinib SCHEMBL30596887 | 0.91 | TYK2 (1.00) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| Zasocitinib SCHEMBL30895694 | 0.89 | TYK2 (0.92) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| Zasocitinib SCHEMBL30895721 | 0.89 | TYK2 (0.92) | TYK2JAK1JAK2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.